Tagged with S

Brazil Juan Pablo Udry, general manager Brazil and Latin America at Boiron, the world’s undisputed leader in homeopathic medicines, provides an insightful overview of the Brazilian and Latin American landscape for homeopathic products and documents Boiron’s commitment to bringing a new alternative to physicians across the continent. He also describes the…

Serbia Aleksandra Miric, a pharmacist with a strong background in industry and development, presents the activities of Pharmanova, the company which she directs and which has built up a leadership position within dietary product manufacturing in Serbia. Can you tell us something about your company? “For Pharmanova, we would like the…

Switzerland Dr. Raymond De Vré, senior VP and head of Business Operations and Strategy, Biologics at Dr. Reddy’s in Switzerland, discusses scaling up the Indian-headquartered company’s biosimilars business globally and the importance of selecting Switzerland as the location for regional headquarters.   The main challenge in the mature markets is the…

Poland Wojciech Sulimierski, general manager of Aspen Poland and CEE, discusses the opening of the regional operations in 2014 and the importance of the CEE region as the company establishes itself in the global pharmaceutical ecosystem. Moreover, he highlights the impact of global acquisitions and the niche area model they have…

Lithuania Rytis Naginevičius, director at software development and market analysis specialist SoftDent discusses the company’s targeted solutions for the pharmaceutical and medical industries. You have a quite unusual profile with no healthcare background before you founded SoftDent in 1998. What are the needs that you identified that made you switch to…

Brazil Cesar Rengifo, senior vice president and area director Emerging Markets West at GSK, the fastest growing multinational company in both Brazil and Latin America, discusses the perfect match between GSK’s product portfolio and the region’s healthcare needs as well as the opportunities it entails for the company and Latin America’s…

Switzerland Kurt Reichen, VP Technical Operations at PaxVax, an American-headquartered fully integrated specialty vaccine company focused on infectious diseases, discusses the establishment of the company’s only site outside of the US in Bern, Switzerland, following the 2014 acquisition of a former Crucell manufacturing site from J&J. The establishment of your Swiss…

Serbia Martin Knapp, managing director of the German Chamber of Commerce in Serbia, highlights how Serbia can further develop a more investment-friendly environment and the progress that the country has already made in this regard. Mr. Knapp, it is your second tenure as the Director of AHK in Serbia. What makes…

Canada Ian Jacobson, CEO of Juno Pharmaceuticals, presents the company’s business model of in-licensing and repurposing generic products. He highlights the successful development of the company’s affiliates in Australia, the UK and South Africa, and his plans to refocus efforts on the Canadian market in the near future, aiming to launch…

Poland Jarek Oleszczuk, country president of AstraZeneca Poland, the leading R&D investor in Poland, discusses the exciting milestones that the company has achieved, including reimbursement of two breakthrough oncology therapies, as well as the company’s addition of 500 staff, representing now a 1,150-strong workforce. Furthermore, he touches on AstraZeneca’s key role…

Lithuania Audrius Tutlys, country manager at Teva Lithuania, highlights the importance of Teva in Lithuania, based not only on its broad product offering but also its manufacturing capabilities and shares his willingness to position Teva as a true partner of the government in making Lithuania a European biotech center. Can you…

Switzerland Jürgen Pohle provides both a fascinating and open account of the latest movements of Neovii; a company that possesses the ability to make decisions at the speed of a startup but also has a heritage dating back to the 1970s. After an outstanding career spanning 25 years with Big Pharma…